National Cancer Institute; Notice of Meeting, 44821 [2017-20487]

Download as PDF Federal Register / Vol. 82, No. 185 / Tuesday, September 26, 2017 / Notices surveillance systems to monitor HIV/ HCV coinfections among low-income or underinsured, racial and ethnic minority populations. HRSA–17–047 recipients and subrecipients will require similar evaluation and technical assistance in order to meet the program’s goals and objectives. Supplemental funding to the existing ETAC is a cost effective and efficient solution that will leverage RAND Corporation’s currently funded infrastructure to include the additional sites funded under HRSA–17–047. Further, this supplemental funding will leverage RAND’s current work by combining and comparing evaluation results across all jurisdictions from both initiatives and facilitate the streamlining and integration of processes and technical assistance. Supplemental funding will also provide opportunities for RAND Corporation to create joint learning networks and build on lessons learned from the initial cohort of jurisdictional sites currently in the second year of implementation. Not issuing this award would result in a lack of evaluation and technical assistance for HRSA–17–047 recipients and subrecipients, which is critical to achieving the initiative’s goal to cure HCV among HIV/HCV coinfected people of color. FOR FURTHER INFORMATION CONTACT: Mr. Adan Cajina, Chief, Demonstration Evaluation Branch, Office of Training and Capacity Development, Division of HIV Domestic Programs, HIV/AIDS Bureau, HRSA, 5600 Fishers Lane, 09N108, Rockville, MD 20857, Phone: (301) 443–3180, Email: acajina@ hrsa.gov. Dated: September 19, 2017. George Sigounas, Administrator. [FR Doc. 2017–20544 Filed 9–25–17; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Frederick National Laboratory Advisory Committee to the National Cancer Institute. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other VerDate Sep<11>2014 18:28 Sep 25, 2017 Jkt 241001 reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will also be videocast and can be accessed from the NIH Videocasting and Podcasting Web site (https:// videocast.nih.gov/). Name of Committee: Frederick National Laboratory Advisory Committee to the National Cancer Institute Date: October 30, 2017. Time: 9:00 a.m. to 5:00 p.m. Agenda: Ongoing and new activities at the Frederick National Laboratory for Cancer Research. Place: National Institutes of Health, 31 Center Drive, Building 31, Wing C; 6th Floor, Conference Room 10, Bethesda, MD 20892. Contact Person: Caron A. Lyman, Ph.D. Executive Secretary, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 7W–126, Bethesda, MD 20892, 240–276–6348 lymanc@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/fac/fac.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) 44821 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the NHLBI Special Emphasis Panel. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Grant Review for NHLBI K Award Recipients. Date: October 17, 2017. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Suite 7202, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Melissa E Nagelin, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7202, Bethesda, MD 20892, 301–435–0297, nagelinmh2@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: September 20, 2017. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–20489 Filed 9–25–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: September 20, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health [FR Doc. 2017–20487 Filed 9–25–17; 8:45 am] Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the BILLING CODE 4140–01–P PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 Center for Scientific Review; Notice of Closed Meetings E:\FR\FM\26SEN1.SGM 26SEN1

Agencies

[Federal Register Volume 82, Number 185 (Tuesday, September 26, 2017)]
[Notices]
[Page 44821]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20487]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Frederick National 
Laboratory Advisory Committee to the National Cancer Institute.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting. The meeting will also be videocast and can be 
accessed from the NIH Videocasting and Podcasting Web site (https://videocast.nih.gov/).

    Name of Committee: Frederick National Laboratory Advisory 
Committee to the National Cancer Institute
    Date: October 30, 2017.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: Ongoing and new activities at the Frederick National 
Laboratory for Cancer Research.
    Place: National Institutes of Health, 31 Center Drive, Building 
31, Wing C; 6th Floor, Conference Room 10, Bethesda, MD 20892.
    Contact Person: Caron A. Lyman, Ph.D. Executive Secretary, 
National Cancer Institute, National Institutes of Health, 9609 
Medical Center Drive, Room 7W-126, Bethesda, MD 20892, 240-276-6348 
lymanc@mail.nih.gov.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: https://deainfo.nci.nih.gov/advisory/fac/fac.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: September 20, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-20487 Filed 9-25-17; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.